MDxHealth Inks Marketing Deal with LI Path for Prostate Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – MDxHealth today said that it has signed a co-marketing agreement with Long Island Pathology to promote MDxHealth's ConfirmMDx for Prostate Cancer test.

LI Path is an independent anatomic and clinical pathology lab serving the New York City metropolitan area, and MDxHealth expects the deal to expand its access to urologists in that market. Financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.